BioSpace News Archive

Phosphorus, a leading preventative genomics company, announced that Co-founder and CEO Alexander Bisignano will present data demonstrating the population health impact of GeneCompass™, the first holistic medical-grade genetic test available at a consumer genomics price point.

DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Kristen Kluska, Director, Equity Research Analyst at Cantor Fitzgerald.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021.

SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), today announced the peer-reviewed publication of a new microscopy-based epitranscriptomic method powered by SeqLL’s tSMS platform in the August issue of Cell Report Methods.

BlackOxygen Organcs is recalling all lots of BlackOxygen Tablets and BlackOxygen Organics Powder due to potential health risks.

Medicenna Therapeutics Corp. today announced the appointment of John H. Sampson, MD, PhD, MBA, to its Board of Directors and the voting results from the Company’s annual meeting of shareholders held today, September 23, 2021 (the “Meeting”).

Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announced updated clinical data, including median overall survival (mOS), from the ASCERTAIN phase 3 trial of INQOVI®.

IceCure Medical Ltd., developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, reported its financial results as of and for the six-month period ended June 30, 2021.

Innovent Biologics, Group. (“Innovent”) (HKEX: 01801), today announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 2 clinical trial (clinicaltrials.gov, NCT05003531) of recombinant anti-interleukin 23p19 subunit antibody injection (R & D code: IBI112) in China.

Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, received the resignation of Mr Peter Anastasiou.